Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY 주식 보고서

시가총액: US$30.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Alnylam Pharmaceuticals 관리

관리 기준 확인 3/4

Alnylam Pharmaceuticals' CEO는 Yvonne Greenstreet, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 $ 8.90M, 11% 로 구성됩니다. 11% 급여 및 89% 보너스(회사 주식 및 옵션 포함). 는 $ 7.47M 가치에 해당하는 회사 주식의 0.038% 직접 소유합니다. 7.47M. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 8.6 년입니다.

주요 정보

Yvonne Greenstreet

최고 경영자

US$8.9m

총 보상

CEO 급여 비율11.0%
CEO 임기2.5yrs
CEO 소유권0.05%
경영진 평균 재임 기간3yrs
이사회 평균 재임 기간8.7yrs

최근 관리 업데이트

Recent updates

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Alnylam RNAi therapy for rare protein disorder gets EU approval

Sep 20

Alnylam to offer $900M convertible senior notes

Sep 12

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Aug 29

Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity

Aug 18

APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win

Aug 04

CEO 보상 분석

Yvonne Greenstreet 의 보수는 Alnylam Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$332m

Dec 31 2023US$9mUS$976k

-US$440m

Sep 30 2023n/an/a

-US$510m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$5mUS$850k

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$981m

Mar 31 2022n/an/a

-US$893m

Dec 31 2021US$9mUS$619k

-US$853m

Sep 30 2021n/an/a

-US$838m

Jun 30 2021n/an/a

-US$887m

Mar 31 2021n/an/a

-US$876m

Dec 31 2020US$3mUS$622k

-US$858m

Sep 30 2020n/an/a

-US$891m

Jun 30 2020n/an/a

-US$846m

Mar 31 2020n/an/a

-US$886m

Dec 31 2019US$3mUS$571k

-US$886m

Sep 30 2019n/an/a

-US$821m

Jun 30 2019n/an/a

-US$858m

Mar 31 2019n/an/a

-US$802m

Dec 31 2018US$3mUS$540k

-US$761m

Sep 30 2018n/an/a

-US$692m

Jun 30 2018n/an/a

-US$570m

Mar 31 2018n/an/a

-US$525m

Dec 31 2017US$985kUS$504k

-US$491m

보상 대 시장: Yvonne 의 총 보상 ($USD 8.90M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).

보상과 수익: 회사가 수익성이 없는 동안 Yvonne 의 보상이 증가했습니다.

CEO

Yvonne Greenstreet (61 yo)

2.5yrs

테뉴어

US$8,895,670

보상

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

리더십 팀

이름위치테뉴어보상소유권
Yvonne Greenstreet
CEO & Director2.5yrsUS$8.90m0.045%
$ 13.9m
Jeffrey Poulton
CFO & Executive VP4.9yrsUS$3.22m0.017%
$ 5.2m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardless than a yearUS$3.32m0.018%
$ 5.7m
Pushkal Garg
Chief Medical Officer9.8yrsUS$3.23m0.0091%
$ 2.8m
Tolga Tanguler
Executive VP & Chief Commercial Officer3.5yrsUS$2.87m0.0055%
$ 1.7m
Timothy Maines
Chief Technical Operations & Quality Officer1.5yrs데이터 없음데이터 없음
Kevin Fitzgerald
Senior VP5.2yrs데이터 없음0.012%
$ 3.6m
Christine Lindenboom
Senior VP of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Piyush Sharma
Chief Ethics & Compliance Officer1.8yrs데이터 없음데이터 없음
Evan Lippman
Chief Corporate Development & Strategy Officer1.8yrs데이터 없음데이터 없음
Kelley Boucher
Chief Human Resource Officer5.2yrs데이터 없음데이터 없음
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Boardno data데이터 없음데이터 없음

3.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: ALNY 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Yvonne Greenstreet
CEO & Director2.8yrsUS$8.90m0.045%
$ 13.9m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardno dataUS$3.32m0.018%
$ 5.7m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board8.8yrs데이터 없음데이터 없음
Peter Kellogg
Independent Director1.3yrsUS$658.72k0%
$ 0
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$516.04k데이터 없음
David E. Pyott
Independent Director8.6yrsUS$477.21k0.022%
$ 6.8m
Phillip Sharp
Co-Founder22.1yrsUS$502.21k0.21%
$ 64.9m
Amy W. Schulman
Independent Chair of the Board & Lead Independent Director10yrsUS$531.36k0.0067%
$ 2.1m
Markus Stoffel
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Bartel
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director12.3yrsUS$477.21k0.0029%
$ 883.3k
Colleen Reitan
Independent Director6.1yrsUS$489.15k0%
$ 0

8.7yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: ALNY 의 이사회는 경험(평균 재직 기간 8.6 년)으로 간주됩니다.